Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
KDMF
0
NDC API
0
VMF
0
FDF
0
FDA Orange Book
0
Canada
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Mistalin
2. Mistamine
3. Mizolen
4. Mizollen
5. Sl 85.0324
6. Sl-85.0324
7. Zolim
8. Zolistan
1. 108612-45-9
2. Mizollen
3. Zolistan
4. Sl 85.0324
5. Mistamine
6. 2-((1-(1-(p-fluorobenzyl)-2-benzimidazolyl)-4-piperidyl)methylamino)-4(3h)-pyrimidinone
7. Mizolastine (mizollen)
8. Mkc-431
9. Chembl94454
10. 2-[[1-[1-[(4-fluorophenyl)methyl]benzimidazol-2-yl]piperidin-4-yl]-methylamino]-1h-pyrimidin-6-one
11. Mistalin
12. 244o1f90na
13. Mizolastine [inn]
14. Ncgc00181013-01
15. Mizolastina
16. Mizolastinum
17. Mizolen
18. Zolim
19. Dsstox_cid_26801
20. Dsstox_rid_81916
21. Dsstox_gsid_46801
22. 2-((1-(1-(4-fluorobenzyl)-1h-benzo[d]imidazol-2-yl)piperidin-4-yl)(methyl)amino)pyrimidin-4(3h)-one
23. 2-[[1-[1-[(4-fluorophenyl)methyl]benzoimidazol-2-yl]-4-piperidyl]-methyl-amino]-3h-pyrimidin-4-one
24. Mizolastinum [inn-latin]
25. Mizolastina [inn-spanish]
26. Zolistam
27. 2-{1-[1-(4-fluorobenzyl)-1h-benzimidazol-2-yl]-4-piperidyl(methyl)amino}pyrimidin-4(1h)-one
28. Sl-85.0324
29. Mizollen (tn)
30. 2-((1-(1-(4-fluorobenzyl)-1h-benzo[d]imidazol-2-yl)-piperidin-4-yl)(methyl)amino)pyrimidin-4(1h)-one
31. Cas-108612-45-9
32. Mizolastine (jan/inn)
33. Mizolastine [inn:ban]
34. Unii-244o1f90na
35. Ccris 8410
36. Sl 850324
37. Mizolastine [mi]
38. Mizolastine [jan]
39. Schembl5061
40. Mizolastine [mart.]
41. Mizolastine [who-dd]
42. Mls006010068
43. Mkc431
44. Dtxsid5046801
45. Bdbm22877
46. Chebi:31857
47. Gtpl10102
48. Hms3713n04
49. Hy-b0164
50. Tox21_112663
51. Ac-634
52. Mfcd23140913
53. Zinc13831810
54. Akos005145756
55. Akos016003409
56. Tox21_112663_1
57. Ccg-220621
58. Cs-1997
59. Db12523
60. Ks-1139
61. Ncgc00344565-01
62. Ncgc00344565-04
63. 4(1h)-pyrimidinone, 2-((1-(1-((4-fluorophenyl)methyl)-1h-benzimidazol-2-yl)-4-piperidinyl)methylamino)-
64. Sl850324
65. Smr003965484
66. Sl-850324
67. Ft-0628955
68. M2756
69. D01117
70. T71584
71. Ab01566892_01
72. 612m459
73. A801901
74. Q417830
75. J-507624
76. Brd-k21884483-001-01-1
77. (4-ethoxy-2-oxo-2,5-dihydro-pyrrol-1-yl)-aceticacid
78. 2-({1-[1-(4-fluoro-benzyl)-1h-benzoimidazol-2-yl]-piperidin-4-yl}-methyl-amino)-3h-pyrimidin-4-one
79. 2-({1-[1-(4-fluorobenzyl)-1h-benzimidazol-2-yl]-piperidin-4-yl}-methylamino)-4(1h) Pyrimidinone
80. 2-[[1-[1-[(4-fluorophenyl)methyl]-2-benzimidazolyl]-4-piperidinyl]-methylamino]-1h-pyrimidin-6-one
81. 2-[[1-[1-[(4-fluorophenyl)methyl]benzimidazol-2-yl]piperidin-4-yl]- Methylamino]-1h-pyrimidin-6-one
82. 2-[[1-[1-[(4-fluorophenyl)methyl]benzimidazol-2-yl]piperidin-4-yl]-methyl-amino]-1h-pyrimidin-6-one
Molecular Weight | 432.5 g/mol |
---|---|
Molecular Formula | C24H25FN6O |
XLogP3 | 3.2 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 5 |
Exact Mass | 432.20738760 g/mol |
Monoisotopic Mass | 432.20738760 g/mol |
Topological Polar Surface Area | 65.8 Ų |
Heavy Atom Count | 32 |
Formal Charge | 0 |
Complexity | 728 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Histamine H1 Antagonists, Non-Sedating
A class of non-sedating drugs that bind to but do not activate histamine receptors (DRUG INVERSE AGONISM), thereby blocking the actions of histamine or histamine agonists. These antihistamines represent a heterogenous group of compounds with differing chemical structures, adverse effects, distribution, and metabolism. Compared to the early (first generation) antihistamines, these non-sedating antihistamines have greater receptor specificity, lower penetration of BLOOD-BRAIN BARRIER, and are less likely to cause drowsiness or psychomotor impairment. (See all compounds classified as Histamine H1 Antagonists, Non-Sedating.)
R06AX25
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
R - Respiratory system
R06 - Antihistamines for systemic use
R06A - Antihistamines for systemic use
R06AX - Other antihistamines for systemic use
R06AX25 - Mizolastine
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Global Sales Information
Market Place
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?